Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Pulmonary Diseases

RT Insights on Safe and Effective IPV Practices for Patients Who Require Ventilatory Support

: Live Meeting
Pulmonary Diseases
: 1.0 AMA PRA Category 1 Credit(s)™; 1.0 contact hour Continuing Respiratory Care Education (CRCE) Credit
Target Audience
: Registered Respiratory Therapists; Physicians who treat patients with Pulm HTN
Expiration Date
: 10/06/2017

Read the content below to launch the activity

Please join us for the CME/CRCE-Certified Symposium at AARC 2017
RT Insights on Safe and Effective IPV Practices for Patients Who Require Ventilatory Support
This activity is supported by an independent educational grant from Mallinckrodt Pharmaceuticals

Friday, October 6, 2017
6:30 AM – 8:00 AM
Breakfast will be available at 6:30 AM

Marriott Ballroom 6, Second Floor
Indianapolis Marriott Downtown
350 West Maryland Street
Indianapolis, IN

There are inherent risks and safety concerns with any ventilatory mode or delivery system and their management and mitigation, including the universal risk of rebound pulmonary hypertension. Key safety features available on different devices will be discussed in detail, including alarm categories and types, as well as essential clinical practices, including patient and device monitoring, adherence to FDA guidelines, accurate dose delivery, avoiding pitfalls in the drug delivery process, maintaining awareness of drug side effects, and instituting appropriate management.

A comparative assessment of each ventilatory mode and delivery system for invasive and non-invasive ventilation, including high flow nasal oxygen, CPAP, conventional ventilators, and high frequency ventilators, will be discussed. Practical issues concerning the use of different delivery systems will also be reviewed.

Learning Objectives
• Differentiate ventilatory devices based on safety features and indications for patients with PHTN
• Identify optimal inhaled pulmonary vasodilator therapy based on the pharmacology, safety, and efficacy of individual agents for patients with PHTN who are candidates for this intervention
• Explain how to approach the use of aerosolized pulmonary dilating agents not formulated or indicated for use by inhalation with the appropriate amount of caution

Program Co-Chairs
Richard D. Branson, MSC, RRT, FAARC, FCCM
Associate Professor of Surgery
Division of Trauma and Critical Care
University of Cincinnati
Cincinnati, OH

Michael D. Davis, RRT, PhD
Assistant Professor
Medical College of Virginia at
Virginia Commonwealth University
Department of Pediatrics
Division of Pulmonary Medicine
Richmond, VA